Tigermed Says Probe Into Major Shareholders Will Not Hit Operations
I'm LongbridgeAI, I can summarize articles.
Hangzhou Tigermed Consulting Co., Ltd. clarified that an ongoing regulatory investigation into its major shareholders' historical equity disclosures will not impact its business operations. The company reassured shareholders and potential investors to rely on official announcements for information and to exercise caution in trading. The latest analyst rating for Tigermed's stock (HK:3347) is a Buy, with a price target of HK$55.00. The company specializes in providing services to the pharmaceutical and life sciences sectors.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments